Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

The Historical Past Around The ABT-888 Accomplishment

The current study was a nonrandomized, multicenter, open-label phase 2 trial in patients with histologically proven CS with nonresectable or metastatic disease. In all patients, the histological diagnosis was centrally reviewed and PDGFR expression was confirmed by immunohistochemical staining. Immunostaining was performed on 4-um thick tissue sections after antigen retrieval by immersion in 0.01 Selisistat nmr M of citrate buffer (pH 6.0) for 40 minutes. Incubation with the primary PDGFR-�� polyclonal antibody (Lab Vision/NeoMarkers, Lab Vision Corporation, Fremont, Calif) and/or PDGFR-�� rabbit polyclonal antibody (Thermo Scientific, Fremont, Calif) were performed for 60 minutes at dilutions of 1:150 and 1:25, respectively. Detection was made using the Envision system (Dakocytomation Inc, Carpinteria, Calif), a polymer-based, biotin-free detection system, for 30 minutes followed by the chromogen 3,3-diaminobenzidine for 10 minutes. The presence of membranous and/or cytoplasmic immunostaining was determined semiquantitatively (ie, <30%, 30%-60%, and >60% positive tumor cells were graded as 1, 2 or 3, respectively). All patients were aged ��18 years Quizartinib and had received at least 1 line of chemotherapy that was completed >4 weeks before trial entry. In addition, any radiotherapy had to be completed >1 month before trial entry. Patients were required ABT-888 molecular weight to have a life expectancy of ��3 months and an Eastern Cooperative Oncology Group performance status <3. All patients received IM at a dose of 400 mg twice a day. According to toxicity, the dose could be reduced or temporarily suspended until recovery from the observed adverse event/s. Therapy was resumed at the maximum tolerated dose according to the physician's decision. Before the initiation of treatment, all patients were staged using computed tomography scans of the chest and abdomen, magnetic resonance imaging (if limb lesions were involved), full blood count and serum chemistry, electrocardiogram, and physical examination. All tests were repeated after 2 months and at 3-month intervals thereafter until disease progression or unexpected toxicity occurred. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).13 Treatment was continued until disease progression or unacceptable toxicity. Response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0).14 According to these criteria, complete response (CR) and partial response (PR) required confirmation within 4 weeks after a response was first demonstrated whereas stable disease (SD) required confirmation within ��8 weeks.</div>
Sign In or Register to comment.